Anti-Thymocyte Globulin (Thymoglobulin), Tacrolimus, and Sirolimus as Acute Graft-versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 11, 2012, Pages 1734-1744

  Al Kadhimi, Zaid ^a   Gul, Zartash ^b   Rodriguez, Roberto ^c   Chen, Wei ^a   Smith, Daryn ^a   Mitchell, Alice ^d   Abidi, Muneer ^a   Ayash, Lois ^a   Deol, Abhinav ^a   Lum, Lawrence ^a   Forman, Stephen ^c   Ratanatharathorn, Voravit ^a   Uberti, Joseph ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

AGVHD; Antithymocyte globulin; Sirolimus; Tacrolimus; Unrelated hematopoietic stem cell transplantation

Indexed keywords

ACICLOVIR; BUSULFAN; CARMUSTINE; COTRIMOXAZOLE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; NORFLOXACIN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BONE MARROW DISEASE; CAUSE OF DEATH; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION COMPLICATION; KIDNEY DYSFUNCTION; LARGE GRANULAR LYMPHOCYTE; LOADING DRUG DOSE; LYMPHOCYTOSIS; LYMPHOMA; MALE; MORTALITY; MYCOSIS; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RECURRENT DISEASE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; AGED; ANTILYMPHOCYTE SERUM; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SIROLIMUS; SURVIVAL RATE; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84867444863     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.06.004     Document Type: Article

References (49)

1. Chang Y.J., Weng C.L., Sun L.X., Zhao Y.T. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Ann Hematol 2012, 91:427-437.
2. Valcárcel D., Sierra J., Wang T., et al. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant 2011, 17:640-648.
3. Weisdorf D.J., Anasetti C., Antin J.H., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002, 99:1971-1977.
4. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
5. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
6. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
7. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989, 73:1729-1734.
8. Chao N.J., Snyder D.S., Jain M., et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000, 6:254-261.
9. Ho V.T., Weller E., Lee S.J., et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001, 7:223-229.
10. Lopes J.A., Jorge S., Silva S., et al. Acute renal failure following myeloablative autologous and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2006, 38:707.
11. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335-340.
12. Powell J.D., Lerner C.G., Schwartz R.H. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999, 162:2775-2784.
13. Wekerle T. T-regulatory cells-what relationship with immunosuppressive agents?. Transplant Proc 2008, 40(10 suppl):S13-S16.
14. Powell J.D., Fitzhugh C., Kang E.M., et al. Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism. Transplantation 2005, 80:1541-1545.
15. Wu T., Sozen H., Luo B., et al. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy. Bone Marrow Transplant 2002, 29:949-956.
16. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004, 10:328-336.
17. Rodriguez R., Nakamura R., Palmer J.M., et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010, 115:1098-1105.
18. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
19. Cutler C., Stevenson K., Kim H.T., et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008, 112:4425-4431.
20. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
21. Russell J.A., Duan Q., Chaudhry M.A., et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008, 14:888-895.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
23. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
24. Litzow M.R., Tarima S., Pérez W.S., et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010, 115:1850-1857.
25. Kröger N., Brand R., van Biezen A., et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009, 94:542-549.
26. Gupta V., Tallman M.S., Weisdorf D.J. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011, 117:2307-2318.
27. Gyurkocza B., Storb R., Storer B.E., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010, 28:2859-2867.
28. Witherspoon R.P., Deeg H.J. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. Haematologica 1999, 84:1085-1087.
29. Yakoub-Agha I., de La Salmonière P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000, 18:963-971.
30. Ballen K.K., Shrestha S., Sobocinski K.A., et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010, 16:358-367.
31. Kim S.W., Tanimoto T.E., Hirabayashi N., et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006, 108:382-389.
32. Delgado J., Milligan D.W., Dreger P. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. Blood 2009, 114:2581-2588.
33. Sorror M.L., Storer B.E., Sandmaier B.M., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008, 26:4912-4920.
34. Fenk R., Liese V., Neubauer F., et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011, 52:1455-1462.
35. Mohty M., Faucher C., Vey N., et al. Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. Leukemia 2002, 16:2129-2133.
36. Rodriguez R., Parker P., Nademanee A., et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 2004, 33:1123-1129.
37. Perkins J., Field T., Kim J., et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16:937-947.
38. Zohren F., Schroeder T., Czibere A., et al. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. Bone Marrow Transplant 2011, 46:747-755.
39. Furlong T., Kiem H.P., Appelbaum F.R., et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008, 14:531-537.
40. Rodriguez R., Nademanee A., Palmer J.M., et al. Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD. Bone Marrow Transplant 2010, 45:205-207.
41. Parmar S., Andersson B.S., Couriel D., et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol 2011, 29:294-302.
42. Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003, 102:1601-1605.
43. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
44. Socieé G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
45. Blaise D., Farnault L., Faucher C., et al. Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Exp Hematol 2010, 38:1241-1250.
46. Remberger M., Sundberg B. Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005, 90:931-938.
47. Rosenbeck L.L., Kiel P.J., Kalsekar I., et al. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:916-922.
48. Ferrara J.L., Guillen F.J., van Dijken P.J., et al. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 1989, 47:50-54.
49. Dolstra H., Preijers F., Van de Wiel-van Kemenade E., Schattenberg A., Galama J., de Witte T. Expansion of CD8+CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br J Haematol 1995, 90:300-307.